Lunacalcipol

Drug Profile

Lunacalcipol

Alternative Names: CTA-018; CTA018 Capsule; CTA018 Cream; CTA018 Injection; Lunacalcipol; MT-2832

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Cytochroma; OPKO Health
  • Class Antipsoriatics; Vitamin D analogues
  • Mechanism of Action Calcitriol stimulants; CYP24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriasis; Secondary hyperparathyroidism

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Feb 2017 Discontinued - Phase-II for Secondary hyperparathyroidism in USA (IV)
  • 23 May 2016 OPKO Health plans a phase IIb trial for Secondary hyperparathyroidism in USA (IV) (OPKO Health website, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top